Off-label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review.
Atopic dermatitis (AD) is a common, chronic type 2 inflammatory skin disease, typically starting in infancy, with increased risk for subsequent extracutaneous atopic morbidities. Dupilumab is the first USFDA-approved biologic agent targeting type 2 inflammation, licensed in 2017 for adults with moderate-severe AD and 2 years later for adolescents. Systemic treatment for pediatric AD remains a significant unmet medical need. To analyze off-label use of dupilumab in children with AD. Multicenter retrospective review evaluated children prescribed dupilumab for moderate-severe AD. 111 (89.5%) of 124 patients gained access to dupilumab after a mean of 9 weeks. The dosing range was 4-15.5 mg/kg load, and 2.0-15.3 mg/kg every other week maintenance, widest for 6-11 year olds, related to use of either full or half adult dosing. Associated morbidities, treatment response, and adverse events were comparable to previous adolescent and adult trials. Retrospective design limited uniform data collection. Access to dupilumab was achievable for the majority of children, after a mean 9-week delay due to insurance denial. This review supports dupilumab response and tolerability in children. Optimal dosing for patients under age 12 has not been defined. Availability in two different concentrations is an important safety issue.